Search Results 1461-1470 of 19401 for hemoglobin

  1. Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis - Mayo Clinic

    Hemoglobin < 10 g/dL; platelet < 100×109/L; absolute neutrophil count < 1.5×109/L. Any contraindication to MRI and/or Gd, eg, any object that is reactive to ...

  2. A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients - Mayo Clinic

    Hemoglobin concentration <9 g/dL at Screening. 12. Subjects treated with an IV or SC prostacyclin pathway agent (eg, epoprostenol, treprostinil, or iloprost) ...

  3. Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure - Mayo Clinic

    Hemoglobin levels less than or equal to 8.0 or greater than or equal to 16.0 g/dL at Screening; White blood cell count less than or equal to 1.5 x 10^9/L or ...

  4. Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT) - Mayo Clinic

    Diagnosed reduced lung function with either diffusion capacity (corrected for hemoglobin) or forced expiratory volume in 1 second (FEV1) ≤65% of predicted ...

  5. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL;; NOTE: Must be met without growth factor support and no transfusions < 14 days prior to testing; Absolute neutrophil count (ANC) ...

  6. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma - Mayo Clinic

    * Hemoglobin > 9.0 g/dL (within 28 days prior to registration) * Absolute neutrophil count ≥ 1.5 x 10^3/uL (within 28 days prior to registration)

  7. Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer - Mayo Clinic

    Hemoglobin >= 9 g/dL; Thyroid stimulating hormone (TSH) < lower limit of normal (LLN) (patients not able to tolerate TSH suppression can be granted an ...

  8. A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL independent of transfusion within 7 days of first dose of study drug. 6. Adequate renal and hepatic function as indicated by: a ...

  9. Intestinal ischemia - Symptoms and causes - Mayo Clinic

    Learn about what happens when blood flow to part of the small or large intestine is blocked, and how this serious condition is treated.

  10. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer - Mayo Clinic

    Obtained =< 21 days prior to registration: Hemoglobin > 9.0 g/dL;; Obtained =< 21 days prior to registration: Total bilirubin =< institutional upper limit of ...